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We report a case of drug-induced immune hemolytic anemia (DIIHA) in an adult female with cystic ﬁbrosis (CF), complicating
routine treatment of a pulmonary exacerbation with intravenous piperacillin-tazobactam. Workup revealed a positive direct
antiglobulin test (DAT) due to red blood cell (RBC)-bound IgG and C3 and piperacillin antibodies detectable in the patient’s
serum. The potential inﬂuence of CF transmembrane conductance regulator mutations on the severity of DIIHA is discussed. This
report illustrates the importance of early identiﬁcation of DIIHA, a rare complication of a commonly utilized medication in CF.
1.Introduction
Chronic infection with bacteria such as Pseudomonas
aeruginosa in CF patients typically leads to progressive
decline in lung function and early mortality [1]. Recent
studies have indicated that more aggressive treatment of
respiratory pathogens with intravenous antibiotics poten-
tially results in better outcomes in aﬀected individu-
als [2]. Piperacillin-tazobactam is an acylureidopenicillin
beta-lactamase inhibitor combination with extended spec-
trum activity against Pseudomonas aeruginosa and is fre-
quently used to treat pulmonary exacerbations. Piperacillin-
tazobactamisanuncommoncauseofdrug-inducedimmune
hemolytic anemia (DIIHA). We present a case of fulminant
intravascular hemolysis due to piperacillin-tazobactam in
a CF patient, review prior reports of this phenomenon,
and discuss possible mechanisms underlying the clinical
presentation of DIIHA in the CF population. Clinicians
should recognize this life-threatening complication of rou-
tine therapy for CF pulmonary exacerbations and under-
stand fundamental aspects of supportive care. This case has
been previously reported in abstract form [3].
2.CaseReport
2.1. Presentation. A 33-year-old, 52.9kg woman with CF
(genotype delta F508/ R560T) was admitted with increased
chest congestion, exertional dyspnea, sputum production,
fatigue, and low-grade fever, symptoms characteristic of
a pulmonary exacerbation. Based on the antimicrobial
susceptibility proﬁle obtained on prior outpatient sputum
cultures, she received piperacillin-tazobactam (4.5gm IV
every 6 hours), ciproﬂoxacin (400mg IV every 12 hours),
azithromycin (500mg by mouth three times per week
chronicallyaspartofheroutpatientregimen),andtrimetho-
primsulfamethoxazole (800mg trimethoprim component
by mouth twice daily) for the treatment of Pseudomonas
aeruginosa and Stenotrophomonas maltophilia. She had pre-
viously received each of these medications without adverse
eﬀect during other hospitalizations. During the night of
her seventh hospital day, she experienced nausea and
violent vomiting. She complained of severe pain in the
back, arms, and chest. She also described weakness and
paresthesias in her extremities and a small blur in the left
inferotemporal visual ﬁeld. On examination, the patient was2 Case Reports in Medicine
anxious, pale, and diaphoretic. There was no fever, and vital
signs included heart rate of 110beats/min, blood pressure
of 106/65mmHg, respiratory rate of 23breaths/min, and
oxyhemoglobin saturation of 100% while breathing room
air. The precordium was hyperdynamic, but her skin was
cool,withlivedoreticularisoverthethighs,knees,andcalves.
Over the subsequent two days, the urine became dark, with a
pink hue.
2.2. Diagnostic Studies. The electrocardiogram and chest
radiograph were unchanged. Laboratory evaluation dis-
closed a hemoglobin level of 4.8g/dL, decreased from
12.2g/dL two days earlier. Arterial blood analysis showed
that the carboxyhemoglobin level was 5.3%. CT scan of
the chest and abdomen did not reveal any acute process,
and she was transferred to the intensive care unit for
further management. Repeat blood count veriﬁed that the
hemoglobin level was critically low at 4.3g/dL, and the blood
smear demonstrated stacked spherocytes. The lactate dehy-
drogenase(LDH)was418U/L,haptoglobin< 20mg/dL,and
total bilirubin 2.4mg/dL. The direct antiglobulin test (DAT)
was strongly positive due to both IgG and C3d. The plasma-
free hemoglobin level was elevated. The following day the
reticulocyte count was 17.5% (index 2.36). Autoimmune
hemolytic anemia (AIHA) was suspected, and no fully
compatible unit of packed red cells could be identiﬁed by
the blood bank. The vitamin E level was 4.9mg/L (normal
range 3.0–15.8mg/L). Seven days after the reaction, a sample
of her serum was sent to American Red Cross Blood Services
in Pomona, California, where piperacillin antibody was
detected by the “immune-complex” method, as previously
described [4, 5]. Brieﬂy, the patient’s serum was tested with
and without the presence of a 1mg per mL solution of
piperacillinagainstuntreatedandenzyme-treatedRBCs.The
patient’s serum caused direct agglutination of e+ RBCs,
but not of e− RBCs in the presence of the drug; the
e− RBCs were, however, sensitized in the presence of the
drug. Enzyme-treated RBCs, both e+ and e−, were slightly
hemolyzed and strongly directly agglutinated in the presence
ofthedrug.Thenegativecontrolswerenonreactive.Thusthe
antipiperacillin demonstrated relative anti-e speciﬁcity.
2.3. Clinical Course. Upon transfer to the intensive care
unit, all antibiotics were discontinued, and the patient was
treated with intravenous crystalloid, methylprednisolone,
morphine, and transfusion of least-incompatible blood.
Chestpainandnausearesolvedwithin24hours.Shereceived
one dose of pooled immune-globulin (IVIG). Following
these treatments, blood counts recovered back to baseline
over three weeks, as illustrated in Figure 1.T h ec a r b o x y -
hemoglobin level returned to normal, and repeat DAT
performed thirteen days later was negative. Funduscopic
examinationbyanophthalmologistwasdescribedasnormal,
except for a possible cotton wool spot in the superior aspect
of the left retina. The patient remained weak and had
persistent joint pains, but her general condition improved
with physical therapy, and the reported visual disturbance
slowly improved over several weeks. She was discharged to
home after 1 month.
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Figure 1: Hemoglobin proﬁle over the hospital course. Timing of
medical interventions is indicated by symbols (two units of packed
red blood cells were given with each transfusion.)
3. Discussion
DIIHA may be a life-threatening complication of antibiotic
therapy. Our patient’s acute chest, back, and joint pain,
accompanied by a rapid drop in hemoglobin and evidence of
systemichypoperfusion,reﬂectsafulminant,life-threatening
hemolytic process. A Naranjo ADR Probability Score of
5 indicates probable association of piperacillin-tazobactam
administration with the emergence of acute hemolysis in this
case [6]. Review of existing case reports suggests that a severe
clinical presentation may be characteristic of piperacillin-
induced immune hemolytic anemia in patients with CF (see
Table 1).
The antibiotics most frequently associated with DIIHA
are cephalosporins (most commonly cefotetan and ceftri-
axone), although over 100 diﬀerent medications have been
directly implicated [14, 15]. Reports of DIIHA attributed
to penicillins in combination with β-lactamase inhibitors,
such as piperacillin-tazobactam, ticarcillin-clavulanate, and
ampicillin-sulbactam, are increasing [14, 16]. The literature
review reveals only piperacillin and piperacillin-tazobactam
as reported causes of DIIHA in patients with CF.
Table 1 shows clinical details of ten reported cases of
piperacillin-induced immune hemolytic anemia. Four of
these cases occurred in patients with CF, raising the ques-
tion of whether piperacillin-related DIIHA has a diﬀerent
pathophysiology or higher incidence in the CF population,
or perhaps simply reﬂects detection or reporting bias in an
intensively monitored population.
DIIHAhasoccurredinpatientsafter7–13daysoftherapy
with piperacillin or piperacillin-tazobactam. The clinical
syndrome is one of acute and severe anemia, which may be
accompaniedbyhemoglobinuria,nausea,chest,backorjointCase Reports in Medicine 3
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pain, diaphoresis, headache, weakness, and paresthesias.
Laboratory studies usually show anemia with spherocytes
(predominantly extravascular hemolysis) or schistocytes
(intravascular hemolysis). Carbon monoxide is a product
of hemoglobin breakdown, created in equimolar amounts
when bilirubin from the alpha methene bridge of heme
is catabolized. Carboxy-hemoglobin levels are commonly
elevated during hemolysis, providing an immediate clue to
clinicians about the presence of DIIHA [17]. Serum tests
available in most hospital laboratories typically indicate a
decreased haptoglobin, increased free hemoglobin, increased
LDH, total bilirubin and unconjugated bilirubin, and pos-
itive DAT for IgG and C3d. Urine will have an increased
urobilinogen and free hemoglobin. Piperacillin antibodies
may show a preference for Rh(e)+ red blood cells (RBCs)
[3, 8, 18].
Continuation of the culprit medication may be lethal
[4]. Patients beneﬁt from rapid initiation of supportive care,
including intravenous crystalloid to restore intravascular
volume and blood transfusion to restore systemic circulation
and oxygen carrying capacity. Although corticosteroids
and/or IVIG are often given, there is no good evidence
that they help suppress immune-mediated hemolysis when
drug-dependent antibodies are involved; most reports of
successful response to steroids involved simultaneous dis-
continuation of the drug, which was probably responsible
for the resolution of hemolysis. Steroids may help when
drug-induced autoantibodies are implicated; these cases are
rarer than those caused by drug-dependent antibodies. We
treated our patient with steroids and IVIG because the
initial serology supported a diagnosis of AIHA. Later, the
piperacillin antibodies were detected and no RBC autoan-
tibodies were present. We believe that the initial results in
which the patient’s serum reacted with all e+ RBCs, without
drug being present, were due to circulating drug-anti-drug
complexes mimicking autoantibody. This phenomenon has
been described previously [14, 16, 19]. Shirey et al. [10,
12] and Johnson [19] warned about confusing piperacillin-
induced hemolytic anemia with a hemolytic transfusion
reaction or AIHA, respectively.
The exact pathophysiology of DIIHA has yet to be
fully elucidated. A number of possible mechanisms have
been recently described and reviewed [14]. Drug antibodies
may be directed at the drug or a combination of drug
and erythrocyte membrane protein [14]. Such antibodies
may combine with drug on the RBC membrane, either
triggering extravascular hemolysis through interaction with
macrophages in the reticuloendothelial system or initiating
acute intravascular hemolysis via complement activation.
While DIIHA is usually associated with extravascular hemol-
ysis, intravascular hemolysis has been reported with many
drugs (e.g., cefotetan and with ceftriaxone, especially in
children) [14, 16]. All but one of the cases involving
piperacillin in which serology or clinical presentation have
been described implicate a complement-mediated intravas-
cular process. Although our patient demonstrated clinical
evidence of massive hemolysis, the LDH and total bilirubin
were only modestly elevated, suggesting a predominantly
extravascular process.
A mechanism that may inﬂuence the pathophysiology of
hemolytic anemia in CF patients involves local nitric oxide
(NO) production in the microcirculation. NO is a potent
vasodilator, allowing RBCs to easily navigate microvascular
interstices. Under normal circumstances, RBCs express ATP
in response to mechanical stress on the cell membrane,
which in turn upregulates endothelial cell NO synthesis
[20, 21]. The cystic ﬁbrosis transmembrane conductance
regulator (CFTR), surface-expressed in RBCs and coupled
to cytoskeletal elements, is essential to transcellular ATP
movement [21]. Red cells from individuals with CF release
markedly reduced levels of ATP in response to deforma-
tion leading to decreased endothelial NO production [21].
This abnormal signaling is compounded in the setting of
hemolytic anemia, where free hemoglobin further scavenges
NO in the microcirculation [22]. We hypothesize that
due to these factors, DIIHA carries an enhanced risk for
intravascular “sludging” and tissue ischemia in individuals
with CF. This might explain the severe clinical course
observed in the described patient, who has a genotype that
results in signiﬁcantly reduced functional CFTR expression
[23].
While the details of membrane abnormalities in the
erythrocytes of CF patients and their signiﬁcance remain to
be fully understood, it is imperative that clinicians recognize
DIIHA and immediately discontinue potentially causative
medications. We recommend formal immunohematologic
characterization of DIIHA in CF patients. Conﬁrmatory
serological testing (testing of patient’s serum in the pres-
ence of a solution of piperacillin against untreated and
enzyme-treated RBCs) may be particularly useful in aﬀected
individuals [5]. It is important to clearly deﬁne DIIHA in
order to safely guide future therapy in a patient population,
where selection of appropriate antibiotics often becomes
increasingly diﬃcult over time.
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